Background-Use of the left internal mammary artery (LIMA) in multivessel coronary artery disease improves survival after coronary artery bypass graft surgery; however, the survival benefit of multiple arterial (MultArt) grafts is debated. , and patients with bilateral internal mammary artery/radial artery (nϭ147) and LIMA/radial artery (nϭ169) had greater 10-year survival (84% and 78%; PϽ0.001) versus LIMA/SV. In multivariate analysis, MultArt grafts remained a strong independent predictor of survival (hazard ratio, 0.79; 95% confidence interval, 0.66 -0.94; Pϭ0.007). Conclusions-In patients undergoing isolated coronary artery bypass graft surgery with LIMA to left anterior descending artery, arterial grafting of the non-left anterior descending vessels conferred a survival advantage at 15 years compared with SV grafting. It is still unproven whether these results apply to higher-risk subgroups of patients.
L ate survival after coronary artery bypass graft surgery (CABG) is improved when the left internal mammary artery (LIMA) is grafted to the left anterior descending artery (LAD). 1,2 LIMA has been recognized as the optimal conduit in CABG because of its superior patency rate and freedom from arteriosclerosis compared with the saphenous vein (SV). 3 In anticipation of additional advantages with the use of a second arterial graft, surgeons currently use the right internal mammary artery (RIMA), 4 -6 radial artery (RA), [7] [8] [9] or gastroepiploic artery as the bypass conduit. 10 Numerous retrospective analyses appear to have documented an incremental survival benefit by increasing the number of arterial grafts, 4,5,9,11 even though not all reports have been similarly favorable. 12 Two independent meta-analyses have corroborated a long-term benefit, 5, 13 and the results of a multicenter prospective randomized controlled trial of single IMA versus bilateral internal mammary artery (BIMA) grafting, which will assess survival at 10 years, are anticipated in 2018. 14 Despite this compelling information in the published literature, multiple arterial (MultArt) grafting is currently performed in Ͻ13% of CABG operations. 15 
Clinical Perspective on p 1030
The purpose of this report is to review the outcome of our experience with surgical revascularization of patients with multivessel coronary artery disease with the primary goal of testing the hypothesis that MultArt CABG will confer a significant long-term survival benefit compared with the conventional standard-of-care CABG using the LIMA to LAD with additional SV grafting (SVG).
primary coronary revascularization either with LIMA and additional SVGs, the LIMA/SV group (nϭ7435), or with MultArt grafts with or without the addition of SVGs, the MultArt group (nϭ1187). Our strategies for MultArt revascularization included 5 subgroups as follows: BIMA/SV (nϭ589) with the use of BIMA and additional SVGs, BIMA only (nϭ271), BIMA/RA (nϭ147), LIMA/RA (nϭ169), and BIMA/RA/SV (nϭ8; Figure 1 ). There were 2 additional cases with the use of RIMA/RA and 1 case with the use of BIMA/gastroepiploic artery.
Excluded from the review were 8334 patients undergoing concomitant cardiac surgical procedures or repeat coronary bypass surgery and those with congenital coronary anomalies or singlevessel disease.
Surgical Procedures
Indications for myocardial revascularization were based on the standard clinical and angiographic criteria. All patients were operated on through a median sternotomy. IMAs were dissected either with electrocautery as a pedicled graft or, more frequently since 2004, with scissors and clips without cauterization as skeletonized conduits. RA was harvested with the use of a harmonic scalpel or electrocautery.
IMAs and RAs were prepared with diluted solution of papaverine applied only topically. Most of the operations were performed with standard cardiopulmonary bypass and few (Ͻ4%) with off-pump coronary artery bypass. Myocardial preservation during cardiopulmonary bypass involved intermittent, antegrade, or retrograde crystalloid or blood cardioplegia (28°C-32°C).
In patients receiving a single arterial graft, the LIMA was grafted almost exclusively to the LAD, and SVGs were grafted to the non-LAD vessels. In patients receiving MultArt grafts, the LIMA was also preferentially grafted to the LAD, although in some surgical strategies, it was used as an in situ graft to the marginal branch of the left circumflex coronary artery with the combined use of in situ RIMA to the LAD. The RIMA was grafted preferentially as an in situ graft through the transverse sinus to the first marginal branch of the left circumflex coronary artery, as a free graft in a composite-T configuration from the side of the LIMA, or less frequently as free graft from the aorta to the left circumflex coronary artery and/or right coronary artery branches. The RA was used as a free graft in a composite-T configuration from the side of the LIMA or as a free graft from the aorta to the left circumflex coronary artery and/or to the right coronary artery branches. SVGs were also used in the MultArt subgroups preferentially to the right coronary system and less frequently to the left circumflex coronary artery branches or diagonal or intermediate coronary vessels. Overall, 41% of RA grafts and 30% of RIMA grafts were anastomosed to the right coronary artery territory in the MultArt group, and 20% of cases in MultArt group were grafted with 1 artery to the LAD and a second artery to the right coronary artery territory with no additional arterial grafting to the left coronary system.
Definition of Terms and Data Collection
With approval of the Mayo Clinic Institutional Review Board and after patient consent was obtained, data were collected retrospectively by conducting a review of our computerized cardiac surgery database. We also reviewed clinical charts for additional information on patient characteristics, operative variables, and early and late mortality. Patient data were analyzed according to the Society of Thoracic Surgeons National Cardiac Surgery Database guidelines and definitions. Operative mortality was defined as all deaths occurring during the hospitalization in which the operation was performed, even if after 30 days, and those deaths occurring after dismissal from the hospital but within 30 days of the procedure unless the cause of death is clearly unrelated to the operation. Late death was defined as any death that is not operative mortality. Follow-up was obtained by the clinical chart review, questionnaires mailed to the patients at regular intervals, and the Social Security Death Index.
Statistical Analysis
Descriptive statistics for categorical variables are reported as frequency and percentage; continuous variables are reported as mean (SD). Categorical baseline variables were compared between MultArt and LIMA/SV patients by use of the 2 test, and continuous baseline variables were compared by use of the 2-sample t test or Wilcoxon rank-sum test as appropriate.
Logistic regression models were used to find univariate and multivariate predictors of operative mortality. The Kaplan-Meier method was used to draw survival curves and to calculate 5-, 10-, and 15-year survival statistics. Cox regression models were used to find the univariate and multivariate predictors of late survival and overall survival. The multivariable model considered all univariate significant variables (PϽ0.05) with model selection using the stepwise method (backward and forward methods resulted in the same model).
To further confirm the results from multivariate modeling method, a propensity score was calculated on the basis of all the baseline variables for each patient, and 2 groups with matched propensity scores were selected. Late survival was then compared between the matched groups by use of Kaplan-Meier estimates and curves.
All statistical tests were 2 sided with the ␣ level set at 0.05 for statistical significance.
Results
Among patients without operative deaths (nϭ8458), follow-up ranged from 3 days to 18.3 years, with a mean of 7.6 years (SDϭ4.6) and median of 7.3 years. Among them, 7951 patients (94%) had follow-up beyond 30 days. The clinical characteristics of the patients with MultArt grafts and those with LIMA/SV grafts are shown in Table 1 . There were significant differences between the 2 unmatched groups. Patients in the MultArt group were younger; had less impaired left ventricular function and lower proportion of female sex; and less frequently had hypertension, diabetes mellitus, chronic lung disease, peripheral vascular disease, previous myocardial infarction, and previous cerebral vascular accident. MultArt patients were more likely to have 2-vessel disease with 2 distal anastomoses. The proportions of patients with clinically important stenosis in the left main coronary artery, those with urgent/emergent surgical priority, patients whose surgeries were performed without the use of a bypass machine, and those with Ն4 distal anastomoses were not significantly different between the 2 groups ( Table 2) . Aortic cross-clamp time was similar in both groups (50Ϯ19 minutes); bypass time was only 10 minutes longer in the LIMA/SV group than in the MultArt group (85Ϯ31 and 75Ϯ30 minutes, respectively).
The results of the univariate logistic regression models predicting operative mortality showed that older patients and patients of female sex, lower body surface area, lower left ventricular ejection fraction, diabetes mellitus, chronic lung disease, renal failure, peripheral vascular disease, previous myocardial infarction, and triple-vessel disease and those with urgent/emergent priority of operation were more prone to operative mortality. Patients who received MultArt grafts had a lower operative mortality rate (0.8% versus 2.1%; Pϭ0.005). However, after adjustment in a multivariate regression model for all differences in predictors of operative mortality between the MultArt group and MultArt subgroups compared with the LIMA/SV group, there was no statistically significant difference in operative mortality (Pϭ0.996). Operative mortality also was not statistically different between matched groups (0.9% for MultArt versus 0.8% for LIMA/ SV; Pϭ0.818).
Kaplan-Meier-estimated late survival rates were significantly higher for patients with MultArt grafts. Late survival was significantly greater for the MultArt group compared with the LIMA/SV group (5-, 10-, and 15-year survival rates were 95%, 84%, and 71% versus 85%, 61%, and 36%, respectively [PϽ0.001], in the unmatched groups and 96%, 83%, and 70% versus 93%, 80%, and 60%, respectively [Pϭ0.0025], in the propensity score-matched groups [including 1134 patients from each group who survived operative mortality]). Figures 2 and 3 show Kaplan-Meier-estimated 15-year survival rates for patients with MultArt grafts compared with patients with LIMA/SV grafts in the unmatched groups and in the propensity score-matched groups, respectively. In both survival curves, there appears to be a progressive separation of the cumulative survival curves favoring patients with MultArt grafts, and importantly, the curve of the LIMA/SV group exhibits a pronounced downsloping and more accelerated separation of the 2 curves at Ϸ8 to 10 years.
We further analyzed late survival in MultArt subgroups versus the LIMA/SV group. Compared with the LIMA/SV group, each of the MultArt subgroups had significantly better Kaplan-Meier-estimated late survival (PϽ0.001). MultArt subgroups with BIMA/SV and BIMA had late survival rates of 97% and 94% at 5 years, 86% and 82% at 10 years, and 76% and 75% at 15 years, respectively; subgroups with the use of BIMA/RA and LIMA/RA had late survival rates of 95% and 93% at 5 years and 84% and 78% at 10 years, respectively (Table 3 and Figure 4 ). The BIMA/RA/SV subgroup had only 8 patients, too few for separate statistical analysis.
To evaluate whether use of MultArt grafts contributed to the survival difference, we analyzed the groups first using the univariate Cox regression model. Because of the large cohort size, almost all differences in patient characteristics and operative variables were identified as predicting late death in our univariate Cox regression model. Late death was significantly reduced in the MultArt group and in each MultArt subgroup compared with the LIMA/SV group (PϽ0.001). All of the identified univariate variables could be accounted for in a multivariate analysis to find those factors that independently predict survival. The multivariate Cox regression model identified older age, lower ejection fraction, hypertension, diabetes mellitus, chronic lung disease, renal failure, peripheral vascular disease, previous myocardial infarction, previous cerebral vascular accident, clinically important stenosis in the left main coronary artery, urgent/emergent surgical priority, off-pump coronary artery bypass, and absence of MultArt grafts as significant independent predictors of late death ( Table 4) .
The multivariate analysis identified the presence of MultArt grafts as a significant independent predictor of survival (Pϭ0.007). The presence of an additional arterial graft to the LIMA reduced the risk of dying by a factor of 0.79 (95% confidence interval, 0.66 -0.94). Among the MultArt subgroups, analysis showed that use of BIMA with additional SVGs had a significant impact on late mortality (Pϭ0.015) compared with LIMA/SV, whereas the other subgroups did not reach statistical significance (Table 5) . Estimated rates of survival at 15 years (Table 6) were significantly higher for patients with MultArt grafts, for both men and women, for those Ͻ65 and those Ͼ65 years of age, for patients with normal left ventricular function, and for those with impaired left ventricular function. MultArt patients had better estimated 15-year survival rates among patients with diabetes mellitus, chronic lung disease, and renal failure, as well as among patients with clinically significant left main coronary artery stenosis, patients with double-and triple-vessel disease, and patients operated on with urgent/emergent surgical priority (PϽ0.001).
To assess the potential of survival rates evolving over time, we stratified the analysis by the year of surgery, before 2001 and after 2001, and the results remained the same. The MultArt grafting group had better late survival rates compared with the LIMA/SV group in both eras.
Discussion
This study, which involved a large cohort of patients with multivessel coronary artery disease, has shown that in isolated CABG performed Ͼ15 years ago with the use of LIMA to the LAD, bypassing the non-LAD targets with at least 1 additional arterial graft was an independent predictor of survival during the succeeding 15 years. The improved survival was seen among both sexes; in patients of all ages; in patients with preserved left ventricular function and those with impaired left ventricular function; in those with preexisting diabetes mellitus, chronic lung disease, or renal failure and those without those risk factors; in patients with clinically significant left main coronary artery disease; in patients with double-and triple-vessel disease; in patients operated on with elective surgical priority; and in those operated on with urgent and emergent surgical priority. Several of these subsets of patients are at the present time excluded at many centers from HR indicates hazard ratio; CI, confidence interval; EF, ejection fraction; PVD, peripheral vascular disease; S/P MI, status post myocardial infarction; S/P CVA, status post cerebral vascular accident; LM, left main; Urgent/Emergent, surgical priority; OPCAB, off pump coronary artery bypass; MultArt, multiple arterial grafting; LIMA, left internal mammary artery; and SV, saphenous vein. HR indicates hazard ratio; CI, confidence interval; EF, ejection fraction; PVD, peripheral vascular disease; S/P MI, status post myocardial infarction; S/P CVA, status post cerebral vascular accident; LM, left main; Urgent/Emergent, surgical priority; OPCAB, off pump coronary artery bypass; LIMA, left internal mammary artery; RA, radial artery; SV, saphenous vein; and BIMA, bilateral internal mammary artery.
being considered to receive MultArt grafting. We present survival estimates that show that the lower mortality rate for patients with MultArt grafting lasted after the initial perioperative period.
Long-term survival after CABG is presumed to be in direct correlation with late patency of the selected conduits and grafts constructed. Thus, the superiority in long-term survival observed among MultArt patients compared with LIMA/SV patients may reflect the accelerated atherosclerosis and intimal fibrosis of vein grafts with their higher probability rates of subsequent closure between 8 and 10 years. 16 The IMA is a living graft with adaptive mechanisms that lead to increased blood flow and resistance to atherosclerosis. Nitric oxide release contributes to the reduced susceptibility of arterial grafts to atherosclerosis. 17, 18 Our study was observational and retrospective. Thus, we cannot rule out additional effects of missing covariates. We also cannot exclude the possibility that the differences between the 2 groups suggest selection preferences that could contribute to better outcome in the MultArt group. However, when we used multivariate models to account for all the differences between the 2 groups of patients, we still found a significant independent survival advantage associated with the use of MultArt grafting. It is important to emphasize that because of the large cohort size, almost all differences between the 2 groups reached statistical significance in the univariate analysis. Thus, all these differences could be controlled for in a multivariate analysis that would identify independent predictors of late survival. We further confirmed our results with a propensity score-matched analysis and were able to match 97% (1153) of the MultArt patients with 1153 LIMA/SV patients. Nonetheless, further stratified analysis should be encouraged to identify exact subgroups that would benefit more from MultArt grafting.
These results showing superior survival with MultArt grafting suggest that the initial selection of MultArt conduits has a more substantial influence on overall and late survival than other variables appearing later after CABG, including the progression of atherosclerosis in the coronaries that were not bypassed or distal to the anastomosis in the grafted coronaries. The survival curves would be expected to resemble each other if the progression of atherosclerosis were the dominant factor.
There are conflicting data from recent studies of the usefulness of MultArt conduits. 19, 20 Ruttmann and coauthors 15 provided strong evidence for the superiority of the RIMA graft compared with the RA as a second conduit in MultArt grafting. They used the RIMA in 82% of cases as an in situ graft routed through the transverse sinus, although BIMAϮSV group had a significantly shorter follow-up than the LIMAϩRAϮSV group. In our study, follow-up was shorter for the MultArt subgroups with the use of RA; thus, we were able to compare estimated survival rates for 10 years in MultArt subgroups and the LIMA/SV group.
It may be reasonable to assume that with a longer follow-up period and a larger number of patients, the LIMA/RA subgroup would eventually present lower survival rates compared with the subgroups that used BIMA. However, even with shorter follow-up, the estimated 10-year survival rate for the whole MultArt group and for each of the subgroups was better than that observed in the LIMA/SV group. Furthermore, in the multivariate analysis, among the MultArt subgroups, there was a significant impact on late survival only in the group that used BIMA with additional SVGs; in the other subgroups, there was not. We attribute this finding to the relative small number of patients in the other MultArt subgroups, implied by their wider confidence intervals.
The diversity in our surgical approach in the MultArt group reflects the complexity of MultArt CABG surgery and the very early realizations that for each CABG procedure, the individual surgeon has to decide which operation can be accomplished for a specific patient that will confer the best short-and long-term outcomes and that many clinical and operative factors must be considered to achieve that goal.
Our MultArt grafting approach consisted of 5 different major surgical strategies with additional variations, as only partially represented in Figure 1 , involving the use of LIMA and/or RIMA and/or RA, with and without the additional use of SVGs, with BIMA in situ grafting versus free RIMA or RA anastomosed to the side of the LIMA constructing a composite-T graft or as free grafts from the aorta, with sequential anastomoses or separate grafts, with the use of pedicled or skeletonized IMAs, and with performing the procedure with or without the use of cardiopulmonary bypass.
The fact that multiple strategies were used in this large group of patients emphasizes further the importance of the second arterial graft. It appears that the specific revascularization method used (which arterial graft for which branch in addition to the LAD) is less important than the fact that a second arterial conduit was used. The results of this study also need to be evaluated with the consideration that the surgeons involved in MultArt grafting are all experienced in coronary surgery in general and in complex arterial grafting in particular.
Coronary surgery concepts continue to evolve. The RA is used as a conduit more frequently than the RIMA, mainly because of concerns of an increased risk of sternal wound infection with the harvest of both internal mammary arteries. From our clinical experience and the experience of others, harvesting the IMA grafts in a skeletonized fashion yields greater graft length and increases flexibility in its use for more distal anastomotic sites. The skeletonized method may also result in higher spontaneous blood flow, preservation of collateral blood supply to the sternum, and lowering of the risk of sternal infection. [21] [22] [23] With the skeletonized technique, multiple vessels can be revascularized without manipulation of the aorta, thus possibly reducing risk of stroke.
Despite previous reports of greater benefit from left than right coronary system grafting with the second arterial graft, 4, 24 careful review of the literature indicates that use of 2 IMA grafts demonstrates excellent long-term results with no demonstrable difference in outcome between right and left coronary system patients. 25, 26 Indeed, in our study, 20% of MultArt patients received the second arterial bypass to the right system only, with no additional arterial grafting to the circumflex coronary system. MultArt grafting makes coronary surgery more complicated. The operation takes longer, is technically more demanding, and is more challenging to teach. There is, however, mounting evidence that late outcome of surgical revascularization is improved when at least 2 arterial grafts are used. This message is important to communicate to patients, cardiologists, and surgeons in an era when percutaneous coronary intervention is the dominant technique for coronary revascularization and is being used even in patients with left main coronary artery stenosis. 27 Our results suggest that MultArt grafting is a powerful surgical tool that should be considered for all CABG patients with the goal to substantially improve their long-term outcome. Additional studies to further clarify subgroups of patients who benefit most from MultArt grafting will be important.
